Shareholders to Vote on Massive 50M Share Authorization Increase and Expanded Equity Plan

summarizeSummary

Relmada Therapeutics is proposing a substantial increase in authorized common stock by 50 million shares and an additional 3 million shares for its equity incentive plan, setting the stage for significant potential future dilution.

check_boxKey Events

• Proposed Increase in Authorized Common Stock

  Shareholders will vote on increasing the authorized common stock from 150,000,000 to 200,000,000 shares, adding 50,000,000 shares. This represents a potential dilution of approximately 47.67% based on current outstanding shares if fully utilized.

• Expansion of Equity Incentive Plan

  The company seeks approval to add 3,000,000 shares to its 2021 Equity Incentive Plan, which could result in approximately 2.86% dilution for employee compensation.

• Annual Meeting Proposals

  These proposals are part of the agenda for the Annual Meeting of Stockholders scheduled for May 27, 2026, alongside routine matters like director elections and auditor ratification.

• Context of Recent Capital Activity

  This filing follows a recent S-3 registration on April 3, 2026, for the resale of 33.68 million shares by investors, and a $100 million financing completed in November 2025, indicating ongoing capital-raising efforts.

auto_awesomeAnalysis

Relmada Therapeutics is seeking shareholder approval for two significant proposals that could lead to substantial future dilution. The company proposes increasing its authorized common stock by 50 million shares, from 150 million to 200 million. With approximately 104.89 million shares currently outstanding, this represents a potential dilution of nearly 48% if all newly authorized shares were issued. Additionally, the company is asking to add 3 million shares to its 2021 Equity Incentive Plan, which could result in approximately 2.86% dilution for employee compensation. These proposals follow a recent S-3 filing on April 3, 2026, for the resale of 33.68 million shares by existing investors, and a $100 million financing round in November 2025. While the company frames these actions as necessary for long-term success and to fund its pipeline after a challenging period, the sheer magnitude of the authorized share increase signals a strong intent for future capital raises or other dilutive events, which could significantly impact existing shareholder value.